Latest News

The Wall Street Journal: Merck nears deal for rare-disease-drug maker Acceleron

Merck is in advanced talks to acquire Acceleron Pharma Inc., according to people familiar with the matter, in a move that would bolster the pharmaceutical giant’s rare-disease business.

The deal for Acceleron, which has a market value of around $11 billion, could be announced this week, assuming talks don’t fall apart, the people said.

Should a deal come together, it would be one of Merck’s

biggest and represent a bet on the treatments for the respiratory and blood diseases that Acceleron

specializes in.

Merck appears to have beaten out other potential suitors for Acceleron including Bristol Myers Squibb Co.,

which already owns a big stake in the company.

An expanded version of this story is available at

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News